|Title:||Access to new cancer medicines in Australia: dispelling the myths and informing a public debate|
|Citation:||Vitry A, Mintzes B, Lipworth W. Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. Journal of Pharmaceutical Policy & Practice. (2016) 9:13. DOI 10.1186/s40545-016-0062-x; NHMRC project grant, App 1080673|
|Abstract:||Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines—claims that are frequently supported by prominent coverage in the Australian media. These claims, while morally and psychologically compelling, tend to ignore the complexity of medicines funding decisions. In this commentary we summarise the current situation regarding the registration and funding of cancer medicines in Australia, elucidate the main challenges associated with access to cancer medicines in the Australian context, and describe some of the steps that have been taken to address these challenges. Keywords: Cancer medicines, Funding, High prices, Consumer engagement, Transparency, Public debate|
|Type of Work:||Article, Letter|
|Type of Publication:||Publisher version|
|Appears in Collections:||Research Papers and Publications. Sydney Health Ethics|
|access-to-new-cancer-medicines-pdf-2016.pdf||415.11 kB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.